- AstraZeneca and partner Merck said Thursday the US Food and Drug Administration had approved their ovarian cancer treatment after it met its primary goal of reducing the risk of disease progression or death compared to a placebo.

The approval was based on positive results from the clinical trial during which ovarian cancer treatment Lynparza reduced the risk of disease progression or death by 70% in patients with advanced ovarian cancer compared to placebo following chemotherapy.

Under the oncology collaboration with Merck and following this new approval for Lynparza, AstraZeneca would receive $70m as ongoing externalisation revenue, AstraZeneca said.

'Women with ovarian cancer are often first diagnosed with advanced disease, which is associated with poor outcomes. In SOLO-1, Lynparza in the first-line maintenance setting reduced the risk of disease progression or death by 70 percent for patients with BRCAm advanced ovarian cancer. Today's approval is a critical advancement and brings us closer to our goal of helping these patients achieve long-term remission,' said Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit, AstraZeneca.

Story provided by